19 02 2016

Lanstead Capital invests £4.4 Million in ImmuPharma plc

Cooley advised Lanstead Capital on its £4.4 million investment in AIM listed ImmuPharma PLC.


Lanstead Capital is a specialist international investment firm that provides equity capital to companies already listed on public markets. The Firm, led by Mark W. Holden, was founded in 2007 and is based in United Kingdom. ImmuPharma PLC is a specialist drug recovery and development company. The company is focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. Lupuzor is the company's most advanced drug candidate and is a treatment for lupus, and life threatening auto immune disease. Ed Lukins (Picture), corporate partner at Cooley's London Office, advised Lanstead Capital. Involved fees earner: Ed Lukins - Cooley LLP;

LATEST ISSUE
Powered by Share Trading

POPULAR ARTICLES
LE FONTI AWARDS 2017 CELEBRATES CORPORATE EXCELLENCES IN DUBAI

14/12/2017

On December 14th, 2017, the world’s leading corporate stars reunited for a spec

LE FONTI AWARDS 2017 CELEBRATE CORPORATE EXCELLENCES IN LONDON

23/10/2017

On October 20th, 2017, the world’s leading corporate stars reunited for a speci

Le Fonti IAIR Awards Take Hong Kong By Storm

21/03/2017

Hong Kong has become a city of bright expansion, culture, and futuristic innovation. Fr

Will Brexit break London's place as FinTech Capital?

17/11/2016

Fintech, it’s described as the disruption in financial services pushed by consume

Le Fonti IAIR Awards 2016 celebrates excellences in London.

17/10/2016

On October 14th, 2016, the world’s leading corporate stars aligned for a momentou